Yusuf Hamied

Yusuf Hamied and Mustafa Hamied will offload the stake through a block deal that translates to a discount of up to 5.25% to Monday's closing price of Rs 955 on NSE

Cipla patriarch Y K Hamied increases stake in co to over 20%

Y KHamied (80), who is the Non-Executive Chairman of the company, has acquired 5.22 percent additional stake from his wife Farida Hamied, thereby taking his total holding in the drug firm to 20.76 percent from earlier stake of 15.54 percent, Cipla said in a regulatory filing.

Cipla promoters to decide on family pact in 'due course'

The main promoter Yusuf Hamied had sought an 'informal guidance' from Sebi on whether the proposed voting agreement among his family members would trigger an open offer.

Watch: Why Yusuf Hamied is one of the Indian Business Icons

Indian Business Icons (IBI) 2015 is a special initiative by CNBC-TV18 for celebrating 15 years of leadership. The endeavour is to form a distinct league of the most powerful business icons. The names are now thrown open to public voting. The icon in focus is Cipla‘s Yusuf Hamied.

How generic asthma drug could 'change the face of Cipla'

On Monday, Mumbai-based generic drugmaker Cipla launched the aerosol copy of GlaxoSmithKline‘s anti-asthma inhaler Adviar in two small European markets – Germany and Sweden – but the move could potentially serve as a precursor to a crack at more lucrative markets such as the US and the UK.

Aiming growth of USD 3-4 bn by 2020: Cipla

On the days to come, Yusuf Hamied, chairman, Cipla, says the pharma major may open units in foreign countries just like its peers.

Mukesh Ambani India's richest for 6th year

With networth of USD 21.5 billion, Mukesh Ambani has retained his title as India's richest person for sixth year in a row, while Mexican business tycoon Carlos Slim has emerged as wealthiest in the world for the fourth consecutive year.

Indian pharma cos welcome 'outsiders' to up global presence

Last few months saw some high profile changes in the managements of Indian pharma companies. Entirely promoter-controlled companies giving way to professional managements brought in from top multinationals to drive global ambitions, reports CNBC-TV18's Archana Shukla.

Don't be a protectionist; allow 100% FDI in pharma: Cipla

Within the pharmaceuticals space, there is a huge divide on the issue of restricting foreign investment into Indian pharma companies. Industry leader and veteran Yusuf Hamied has spoken against the Indian pharmaceutical alliance lobbying to restrict foreign companies buying into Indian businesses.

Cipla to see growth of 14% this year: Chairman

Drugmaker Cipla expects to meet domestic industry growth of 14% this year, its chairman said on Thursday, but warned of a possible slowdown in its business in Libya, Syria and Algeria due to the political situation in those nations.